Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.
Sara Valpione, Matteo S Carlino, Joanna Mangana, Meghan Mooradian, Grant A McArthur, Dirk Schadendorf, Axel Hauschild, Georgina V Long, Ana M Arance, Paolo Antonio Ascierto, Michele Maio, Francesco De Rosa, James MG Larkin, John J Park, Simone M Goldinger, Keith Flaherty, Wen Xu, Elisabeth Livingstone, Michael Weichenthal, Paul Lorigan
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017
9512 Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse outcomes for patients (pts) retreated with BRAF-directed therapy. Methods: 116 pts who received BRAFi based therapy and, after a break, were re-challenged with BRAFi +/- MEKi treated at 14 centres in Europe, US, and Australia were analysed for progression free survival (PFS) and response rate (RR), as well as factors predicting overall survival (OS) (demographics, disease stage, treatment, LDH..View full abstract